The Immunological Basis for Treatment of Multiple Sclerosis
- 1 October 2007
- journal article
- review article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 66 (4), 374-382
- https://doi.org/10.1111/j.1365-3083.2007.01982.x
Abstract
During the last few years, the concept of multiple sclerosis (MS) as a pure inflammatory disease mediated by myelin reactive T cells has been challenged. Neither the specificity nor the mechanisms triggering or perpetuating the immune response are understood. Genetic studies have so far not identified therapeutic targets outside the HLA complex, but epidemiological and immunological studies have suggested putative pathogenetic factors which may be important in therapy or prevention, including the Epstein-Barr virus and vitamin D. Advances in the treatment of MS have been reached by manipulating the immune response where the pathogenesis of MS intersects experimental autoimmune encephalomyelitis, most recently by blocking T-cell migration through the blood-brain barrier. Antigen-specific approaches are effective in experimental models driven by a focused immune response against defined autoantigens, but MS may not fit into this concept. Novel candidate autoantigens which are not constitutively expressed in the brain, such as protein alpha-B crystallin or IgG V-region idiotopes, as well as evidence of pathogenetic heterogeneity and complexity, suggest that treating MS by tolerizing the immune system against an universal MS antigen may be a fata morgana. Further characterization of MS subtypes may lead to individualized treatment. However, shared immunological features, such as intrathecal production of oligoclonal IgG, suggest that potential therapeutic targets may be shared by most MS patients.Keywords
This publication has 90 references indexed in Scilit:
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II‐defined cohort of patients with progressive multiple sclerosis: results of a 24‐month double‐blind placebo‐controlled clinical trial and 5 years of follow‐up treatmentEuropean Journal of Neurology, 2006
- Grey matter pathology in multiple sclerosisActa Neurologica Scandinavica, 2006
- Role of return migration in the emergence of multiple sclerosis in the French West IndiesBrain, 2005
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- Antigen-Specific Therapies in Multiple Sclerosis: Going Beyond Proteins and PeptidesInternational Reviews of Immunology, 2005
- Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?The Journal of Experimental Medicine, 1999
- A genetic basis for familial aggregation in multiple sclerosisNature, 1995
- Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple SclerosisScience, 1993
- T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosisNature, 1990